Always love talks from #DrElKrief. For those that haven't read her piece in @JCO_ASCO on the #intratumoral #microbiome in #lungcancer, please have a look: ascopubs.org/doi/10.1200/JCO…

Our reconstructed individual patient data meta-analysis aiming to identify populations that may benefit from dual immune checkpoint blockade with CTLA-4 and PD-(L)1 inhibition has just been published in @TheLancetOncol thelancet.com/journals/lanon… 1/6

🚨 Excited to share our 2 new studies published today in @TheLancetOncol — one offering deeper insight into refining #ICI for PD-L1–negative & 🧬#STK11-mutant #NSCLC, and the other exploring #ICI vs 💊#BRAF/MEKi in #BRAF V600E #NSCLC. @OncoAlert @IASLC #LCSM. /W✨@DiFedericoMD✨ These studies aren’t full answers — but we hope they help sharpen strategies and spark further progress in tailoring immunotherapy for NSCLCs historically seen as resistant. Heartfelt thanks to the co-authors, patients, collaborators & reviewers who made this possible. @marinagarassino @MarceloCorassa @peters_solange @pecci_federica1 @ACortelliniMD @dplanchard @RobertoFerrara_ @CoreyLangerMD @FawziAbuRous @mihaela_aldea @XinAnnWang @DanaFarber @DanaFarberNews @DrMarkAwad @NIVokes @StephenVLiu @NarjustFlorezMD @alessi_joao @DrJNaidoo @Alfdoc2

Precision oncology keeps getting more precise 🔬✨ 🚨Just published in @CCR_AACR our study: First-line MET TKIs vs immunotherapy ± chemotherapy in #METex14 #NSCLC ✦ ICI±chemo showed benefit in tumors with very high PD-L1 ✦ MET TKIs extended survival in patients with lower PD-L1 or brain/bone involvement 🧠🦴 Grateful to have co-led this collaborative effort together with @LeXiuning w/ 💫 1st authors @pecci_federica1 & #HuiLi 💡 Moving beyond single biomarkers toward treatment strategies informed by the intersection of genomics and clinical context. @OncoAlert @DanaFarber @DanaFarberNews @MDAndersonNews @ @Alfdoc2 Link: aacrjournals.org/clincancerr…

On a new episode of Lung Cancer Considered, host @NarjustFlorezMD talks w/ @BRicciutiMD & @g_mountzios about resistance to immune checkpoint inhibitors, STK11/KEAP1/KRAS co-mutations, and emerging NSCLC therapeutics. 🎙️ Listen: bit.ly/LCCColdTumors

#TumorBoardTuesday 🫁Move back to Lung Cancer #NSCLC 📢Join us Tuesday, 08-05-25 at 8PM ET as @biagioricciutMD & @DiFedericoMD 🗣️Frontline IO Strategies for STK11/KEAP1-Mutant metastatic #NSCLC RT and bring others into the discussion‼️

Neoadjuvant PD-1/PD-L1 blockade combined with chemotherapy improved pathological response rates and surgical resectability in patients with T4 and/or N2-N3 stage III NSCLC. ja.ma/4kXyeAx @EdoardoGarbo

Pulmonary sarcomatoid carcinoma is a rare NSCLC histology that every thoracic oncologist has or will face in their practice. In this study led by Dr. Lingzhi Hong & @NIVokes @MDAndersonNews, we characterized features & outcomes of patients w/ these tumors jto.org/article/S1556-0864(2…

Listen to this week's episode of the VJOncology Podcasts featuring @alessi_joao and @DiFedericoMD who discussed #LungCancer updates from #ASCO25 🎧Listen here tinyurl.com/yf7f3az7 They explore the potential of new agents like tarlatamab, and dive into pivotal trials in NSCLC: 🔹 OptiTROP-Lung03 (sacituzumab tirumotecan) 🔹 CheckMate 816 (neoadjuvant nivo + chemo) 🔹 ALNEO (alectinib in ALK+) @ASCO #LCsm #NSCLC This podcast is available on the Lung Cancer Channel on VJOncology, which is supported by Takeda. Supporters have no influence over the production of content.

Factors associated with disease progression after discontinuation of immune checkpoint inhibitors for immune-related toxicity in patients with advanced NSCLC. brnw.ch/21wTZdj

Pleased to discuss some of the ASCO 2025 lung cancer highlights with my dear friend and colleague @alessi_joao in this @VJOncology podcast 👇

Phase III AIM-HIGH trial (@LancetRespirMed) by @DavidRSpigel et al. reports that adjuvant chemotherapy in resected stage IA–IIA non-squamous #NSCLC patients with a high-risk 14-gene score increased 2-year disease-free survival from 79% to 96%. @OncoAlert thelancet.com/journals/lanre…

Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements brnw.ch/21wTyDv By Seshiru Nakazawa, @pecci_federica1, Igor Odintsov, Pasi Janne, @DrMarkAwad, and colleagues @DanaFarber @MSKCancerCenter

Such a privilege to listen to Dr. Crinò—my first mentor—reflecting on 20 years of progress in #LungCancer treatment, from targeted therapies to immunotherapies. A masterclass in science and dedication in #Ferrara 🇮🇹. @OncoAlert @DanaFarber @iascl

🎥 @DiFedericoMD of @DanaFarber highlights key biomarkers from FRONT-BRAF: PD-L1 ≥1%, smoking history & TP53 co-mutations predict better outcomes with immunotherapy in BRAF-mutated lung cancer. 📺 Watch ➡ ow.ly/9oZ250W4OOj @ASCO #ASCO25 #LungCancer #NSCLC #ImmunoOnc

‼️Excited to share our @ASCO edu book article on DLL3 targeting in SCLC. Probably one of the most extensive and Upto date reviews on this topic! Led by @Ayeshaaijaz @SagalPannu We talk about biology, trials, other T cell engagers , tox and much more! ascopubs.org/doi/10.1200/EDB…

Still struck by the impact our microbiome has on efficacy (and toxicity) of immunotherapy in lung cancer. Listen to this episode of the @IASLC podcast, Lung Cancer Considered, where I discuss the data with Drs. Arielle Elkrief and Bertrand Routy. iaslc.org/iaslc-news/lung-ca…

Zoldonrasib (mutant selective covalent inhibitor targeting the ‘ON’ state of RAS G12D. Most patients were PDAC but included NSCLC. #AACR25 @KRASKickers @AACR #lcsm

Just published in @CCR_AACR our work studying factors associated with prolonged disease control and survival after discontinuation of immune checkpoint inhibitors for irAEs in patients with advanced NSCLC. @DrMarkAwad @rohit_thum @AdamJSchoenfeld doi.org/10.1158/1078-0432.CC…

In a new study published in @CCR_AACR, @DanaFarber researchers found the effects of immunotherapy can last after treatment stops in patients with advanced non-small cell lung cancer. @DFarberThoracic Read more: bit.ly/3GhpAhM